Compare DraftKings Inc (DKNG) vs Mesoblast Limited (MESO) Price & Performance

DraftKings IncTrade

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

DraftKings Inc vs Mesoblast Limited — how do they compare? DraftKings Inc trades at $25.23 (market cap $12.58B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: DraftKings Inc is far larger — about 5.7× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.

	DKNG	MESO
Market Cap	$12.58B	$2.21B
Sector	Consumer Cyclical	Technology
52-Week High	$48.23	$20.96
52-Week Low	$20.72	$12.88
Enterprise Value	$13.51B	$2.21B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

DKNG

DraftKings faces decline as prediction markets outpace traditional sportsbooks, shares down 30% YTD.Seeking Alpha · 2 days agoBearish DraftKings Q2 misses earnings but shows strong growth in Predictions platform, stock remains a hold ahead of NFL season.24/7 Wall Street · 2 days agoNeutral View details →

MESO

View details →

About DraftKings Inc

DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.